ALLO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
4.6M
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
4.6M
0
0
0
0
Operating Expenses
51.6M
+11.9%
46.1M
+8.7%
42.4M
-5.6%
44.9M
-21.0%
56.8M
R&D
30.7M
-4.0%
32.0M
+11.8%
28.6M
-8.1%
31.2M
-22.4%
40.2M
SG&A
20.8M
+47.9%
14.1M
+2.3%
13.8M
+0.3%
13.7M
-3.8%
14.3M
Operating Income
-46920000
-1.8%
-46092000
-8.7%
-42404000
+5.6%
-44901000
+21.0%
-56819000
EBITDA
-44275000
-2.4%
-43223000
-9.9%
-39347000
+5.9%
-41804000
+18.6%
-51331000
Net Income
-42677000
-0.2%
-42607000
-9.8%
-38810000
+6.3%
-41400000
+18.7%
-50943000
EPS (Basic)
$-0.13
+27.8%
$-0.18
-5.9%
$-0.17
+10.5%
$-0.19
+17.4%
$-0.23
EPS (Diluted)
$-0.13
+27.8%
$-0.18
-5.9%
$-0.17
+10.5%
$-0.19
+17.4%
$-0.23
Shares (Diluted)
328.9M
+36.9%
240.3M
+6.2%
226.2M
+1.9%
222.0M
+1.4%
218.9M
Allogene Therapeutics (ALLO) โ€” Financials